Rocket Pharmaceuticals (RCKT) Long-Term Deferred Tax (2016)

Rocket Pharmaceuticals (RCKT) posted Long-Term Deferred Tax of $458000.0 for Q4 2016.

Rocket Pharmaceuticals (RCKT) Long-Term Deferred Tax (2016) Analysis & Trends

Rocket Pharmaceuticals has reported Long-Term Deferred Tax for 1 years, with the latest figure at $458000.0 in Q4 2016.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $458000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $458000.0 (changed N/A YoY) and the FY2016 annual result came in at $458000.0, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $458000.0 in Q4 2016 per RCKT's latest filing.
Over five years, Long-Term Deferred Tax peaked at $458000.0 in Q4 2016 and troughed at $458000.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Rocket Pharmaceuticals	380.92 Mn	380.92 Mn	-

Download Data

Date	Value
Dec 31, 2016	458,000.00